Frank X. Leonard - 27 Feb 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Executive Officer
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.
Issuer symbol
NVCR
Transactions as of
27 Feb 2026
Net transactions value
-$230,585
Form type
4
Filing time
03 Mar 2026, 16:09:33 UTC
Previous filing
04 Nov 2025
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Leonard Frank X Chief Executive Officer C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE Steven Robbins, as attorney in fact for Leonard, Frank X. 03 Mar 2026 0001822879

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Sale $133,003 -9,734 -2.8% $13.66 338,011 27 Feb 2026 Direct F1, F2
transaction NVCR Ordinary Shares Award $0 +18,621 +5.5% $0.000000 356,632 28 Feb 2026 Direct F3
transaction NVCR Ordinary Shares Sale $97,581 -7,232 -2% $13.49 349,400 02 Mar 2026 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.
F3 Represents vesting of performance-based restricted stock units.
F4 This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price.